Table 4.
Prognostic factors related to OS and PFS
| Factor | N | Median OS (months) (95% CI) | P-value | Median PFS (months) (95% CI) | P-value |
|---|---|---|---|---|---|
| Age at diagnosis | 0.66 | 0.088 | |||
| 14–44 years | 18 | 28 (0–58) | 31 (0–63) | ||
| ≥45 years | 6 | 19 (13–25) | 6 (0–16) | ||
| Sex | 0.50 | 0.74 | |||
| Male | 12 | 19 (0–38) | 31 (2–61) | ||
| Female | 12 | 28 (7–49) | 11 (4–19) | ||
| Number of previous lines | 0.40 | 0.52 | |||
| 1 | 7 | 26 (NA) | NR | ||
| >1 | 17 | 16 (0–43) | 14 (2–27) | ||
| Duration response prior GemOx | 0.85 | 0.89 | |||
| 0–12 months | 21 | 26 (12–40) | 17 (3–32) | ||
| >12 months | 3 | 28 (0–62) | 14 (1–27) | ||
| Status at GemOx | 0.34 | 0.56 | |||
| PR or relapse | 15 | 28 (10–46) | 17 (0–40) | ||
| Refractory | 9 | 19 (0–38) | 9 (0–19) | ||
| Ann Arbor stage at diagnosis | 0.56 | 0.081 | |||
| I–II | 11 | 16 (0–37) | 6 (2–10) | ||
| III–IV | 13 | 34 (13–54) | NR | ||
| B symptoms at diagnosis | 0.10 | 0.024 | |||
| No | 12 | 34 (0–70) | 31 (NA) | ||
| Yes | 12 | 16 (6–27) | 6 (0–12) | ||
| Bulky disease at diagnosis | 0.78 | 0.77 | |||
| Yes | 6 | 28 (23–33) | 4 (0–15) | ||
| No | 16 | 16 (4–29) | 17 (2–33) | ||
| IPS at diagnosis | 0.26 | 0.22 | |||
| 0–2 | 12 | 99 (NA) | 31 (NA) | ||
| 3–7 | 11 | 26 (12–039) | 9 (2–16) | ||
| Response to GemOx | 0.064 | <0.001 | |||
| CR | 9 | 99 (NA) | NR | ||
| PR | 8 | 26 (0–56) | 17 (11–24) | ||
| Refractory | 7 | 13 (3–23) | 2 (0–5) | ||
| Response to GemOx | 0.043 | 0.062 | |||
| CR | 9 | 99 (NA) | NR | ||
| Less than CR | 15 | 19 (0–38) | 11 (0–23) | ||
| Consolidation with SCT | 0.14 | <0.001 | |||
| Yes | 10 | NR | NR | ||
| No | 14 | 16 (7–26) | 6 (2–11) | ||
| Consolidation with type SCT | 0.14 | 0.001 | |||
| Allo-SCT | 5 | 6 (0–35) | NR | ||
| ASCT | 5 | NR | NR | ||
| No | 14 | 16 (7–26) | 6 (2–11) |
Abbreviations: OS, overall survival; PFS, progression-free survival; N, number; CI, confidence interval; NA, not available; NR, not reached; GemOx, gemcitabine and oxaliplatinum; PR, partial response; IPS, International Prognostic Score; CR, complete response; SCT, stem cell transplantation; Allo-SCT, allogeneic stem cell transplantation; ASCT, autologous stem cell transplantation.